The Filing Desk

Mirum Pharmaceuticals

MIRM · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

MIRM · Last close · November 13, 2026
$93.99
Value Mirum Pharmaceuticals yourself

Mirum Pharmaceuticals' revenue rose 54.7% to $521 million in fiscal 2025. Its operating margin was −4.2%, up from −26.0% a year earlier. Free cash flow was $55 million, up 488.0%. The diluted share count rose 5.6%.

Mirum Pharmaceuticals, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 25, 2026 · 0001759425-26-000013 Updated
Revenue
$521M
54.7%
Operating margin
−4.2%
21.8 pts
Net income
−$23M
 
Free cash flow
$55M
488.0%
Return on capital
−7.1%
19.4 pts
Market cap
$6.2B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Mirum Pharmaceuticals does

Mirum Pharmaceuticals develops and sells medicines for rare diseases. It has three approved medicines. Livmarli (maralixibat) is a pill that treats itching from bile flow problems (cholestatic pruritus) in people with Alagille syndrome and progressive familial intrahepatic cholestasis, two rare liver diseases. It is approved in the United States, the European Union and other countries. Cholbam (cholic acid) treats bile acid synthesis disorders, and Ctexli (chenodiol) treats cerebrotendinous xanthomatosis, a rare inherited disease.

Mirum sells Livmarli with its own commercial team in the U.S., Canada and some European countries. It has also signed license and distribution agreements with other rare-disease companies to sell Livmarli in additional countries. It is testing Livmarli for itching in other rare conditions in a study called EXPAND.

In August 2023 it bought the assets for Cholbam and chenodiol from Travere Therapeutics. It also has product candidates in development, including brelovitug.

Its biggest risks, as it describes them

  • It may not be able to grow its marketing and sales capabilities, or keep needed rights from partners.
  • It may not get or keep adequate coverage and reimbursement for its medicines.
  • Its medicines may fail to win acceptance among doctors, patients and others.
  • Its medicines face ongoing regulatory obligations that could bring added costs or penalties.
  • Its product candidates need substantial clinical testing, and trial enrollment can be slow.
From Mirum Pharmaceuticals's annual report on Form 10-K, filed February 25, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Mirum Pharmaceuticals lost money in fiscal 2025: a net loss of $23 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments156152286280383
Debt incl. finance leases—0306308310
Net debt (negative means net cash)—−1522028−74
Net debt to EBITDA————−34.9x
Debt to equity—0.0x1.2x1.4x1.0x
Interest coverage—−8.2x−7.2x−6.1x−1.5x
Current ratio3.9x2.9x4.5x3.1x2.7x
Quick ratio3.9x2.9x4.2x2.9x2.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Mirum Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Mirum Pharmaceuticals says to expect

  • Full year 2026: net product salesCommercial: Raising Full-Year Net Product Sales Guidance to $715 Million to $720 Million
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 3, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $9.0 million of Mirum Pharmaceuticals shares on the open market, and 8 insiders sold $42.9 million, $25.8 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 11, 2026Laura BregeDirectorSold14,167$94.21$1.3 millionForm 4
Sep 14, 2026Eric BjerkholtChief Financial OfficerSold9,943$98.37$978,093Form 4
Sep 2, 2026Jolanda HoweSVP, Global ControllerSold plan658$100.00$65,800Form 4
Sep 1, 2026Christopher PeetzChief Executive Officer, DirectorSold plan30,000$98.68$3.0 millionForm 4
Aug 18, 2026Jolanda HoweSVP, Global ControllerSold40,000$100.00$4.0 millionForm 4
Aug 11, 2026Eric BjerkholtChief Financial OfficerSold plan6,001$99.90$599,500Form 4
Aug 10, 2026Christopher PeetzChief Executive Officer, DirectorSold plan20,000$98.92$2.0 millionForm 4
Aug 3, 2026Jolanda HoweSVP, Global ControllerSold plan1,840$105.29$193,734Form 4
Jul 6, 2026Christopher PeetzChief Executive Officer, DirectorSold plan20,000$122.27$2.4 millionForm 4
Jul 6, 2026Eric BjerkholtChief Financial OfficerSold plan5,000$122.25$611,273Form 4
Jul 1, 2026Jolanda HoweSVP, Global ControllerSold plan2,721$120.00$326,520Form 4
Jun 17, 2026Jolanda HoweSVP, Global ControllerSold plan2,594$101.95$264,458Form 4
The latest 12 of 43 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 84 of 85 of 8
Rule of 40103.7%83.5%65.3%
Altman Z''−0.23−0.870.54
Accruals ratio−18.5%−14.9%−10.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailPassPass
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassPass
Current ratio rosePassFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailPass
F-score3 of 84 of 85 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Mirum Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Mirum PharmaceuticalsFY2554.7%−4.2%10.5%−7.1%−34.9x5
Travere TherapeuticsFY25110.5%−12.8%———7Compare
OPKO HealthFY25−14.9%−19.4%−31.4%−7.0%—4Compare
InnovivaFY2514.7%39.8%47.6%17.9%—6Compare
ArdelyxFY2522.1%−10.1%−10.8%−36.1%—2Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue—01977186337521
Revenue growth———302.7%141.8%80.8%54.7%
Gross profit———————
Research and development4382131107103141186
Operating income−55−104−173−131−109−88−22
Net income−53−103−84−136−163−88−23
Diluted EPS (US$)−4.58−4.09−2.77−4.02−4.00−1.85−0.47
Diluted shares (millions)12253034414850
Cash flow
Cash from operations−39−89−133−120−711056
Capital expenditure0000011
Free cash flow−40−89−133−120−71955
Dividends paid0000000
Share buybacks0000000
Acquisitions000021300
Stock-based compensation6132327354871
Balance sheet at fiscal year end
Cash and short-term investments117232156152286280383
Debt incl. finance leases———0306308310
Total assets147241295353647671843
Total liabilities1669174211398445528
Shareholders' equity130172120142249226315
Margins and ratios
Gross margin———————
Operating margin——−906.1%−170.3%−58.6%−26.0%−4.2%
Net margin——−438.9%−176.1%−87.7%−26.1%−4.5%
Free cash flow margin——−693.8%−156.3%−38.1%2.8%10.5%
Rule of 40 (growth + FCF margin)———146.4%103.7%83.5%65.3%
Return on capital————−66.6%−26.5%−7.1%
Return on equity—−68.3%−57.5%−103.5%−83.7%−37.1%−8.7%
Return on assets—−53.3%−31.4%−41.9%−32.7%−13.3%−3.1%
Net debt to EBITDA——————−34.9x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Mirum Pharmaceuticals' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Mirum Pharmaceuticals.